|
|
|
|
|
Pemirolast
drug data and news
Pemirolast drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pemirolast | ||
| Brand Names/Synonyms | Alamast; Pemirolast; Pemirolast Potassium; Pemirolastum [Inn-Latin]; Pemiroplast Potassium | ||
| Indication | For the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Pemirolast is used for the prophylactic treatment of itching of the eye associated with allergic conjunctivitis. Pemirolast potassium is a mast cell stabilizer that inhibits the in vivo Type I immediate hypersensitivity reaction. Pemirolast inhibits the antigen-induced release of inflammatory mediators (e.g., histamine, leukotriene C4, D4, E4) from human mast cells. Allergic reactions lead to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, Pemirolast is a histamine H1 antagonist. It competes with histamine for the normal H1-receptor sites on effector cells of blood vessels. It provides effective, temporary relief of watery and itchy eyes. | ||
| Mechanism Of Action | Pemirolast binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Pemirolast has also been observed to block antigen-stimulated calcium ion influx into mast cells. Pemirolast inhibits the chemotaxis of eosinophils into ocular tissue, and prevents inflammatory mediator release from human eosinophils. | ||
| Pemirolast News (When available) |
| ||
| Dosage Forms | Ophthalmic Solution | ||
| Drug_Category | Anti-allergic Agents; Ophthalmics; Antipruritics; Histamine Antagonists | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Pemirolast: No specific information available. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 10-methyl-4-(2H-tetrazol-5-yl)-2,6-diazabicyclo[4.4.0]deca-1,3,7,9-tetraen-5-one | ||
| Chemical Formula | C10H8N6O | ||
| Molecular Weight | 228.21 g/mol | ||
| Smiles String | CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3 | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | -0.192 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic (Ophthalmic) | ||
| Half Life | 4.5 hours (Ophthalmic) | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pemirolast.html http://www.rxlist.com/cgi/generic/alamast.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00394 | ||
| CAS Registry Number | 100299-08-9 | ||
| KEGG Compound ID | C12485 | ||
| PubChem ID | SID:654148 | ||
| PharmGKB ID | PA10285 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |